CBL: an adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling. Participates in signal transduction in hematopoietic cells.
Protein type: Adaptor/scaffold; EC 6.3.2.-; EC 6.3.2.19; Ligase; Motility/polarity/chemotaxis; Oncoprotein; Ubiquitin conjugating system; Ubiquitin ligase
Chromosomal Location of Human Ortholog: 11q23.3
Cellular Component: cytosol; flotillin complex; lipid raft; plasma membrane
Molecular Function: cadherin binding; ephrin receptor binding; protein binding; receptor tyrosine kinase binding; SH3 domain binding; transcription factor activity; ubiquitin-protein ligase activity
Biological Process: cell surface receptor linked signal transduction; epidermal growth factor receptor signaling pathway; fibroblast growth factor receptor signaling pathway; negative regulation of apoptosis; negative regulation of epidermal growth factor receptor activity; negative regulation of epidermal growth factor receptor signaling pathway; positive regulation of epidermal growth factor receptor signaling pathway; positive regulation of phosphoinositide 3-kinase cascade; positive regulation of receptor-mediated endocytosis; protein ubiquitination; protein ubiquitination during ubiquitin-dependent protein catabolic process; transforming growth factor beta receptor signaling pathway
Disease: Juvenile Myelomonocytic Leukemia; Noonan Syndrome-like Disorder With Or Without Juvenile Myelomonocytic Leukemia
Show more